WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
P.O.Box 4404 Nydalen
0403 Oslo
Norway

Visiting/delivery address:
Marcus Thranes gate 6
0473 Oslo
Norway

Tel:  +47 21 07 81 60
Fax: +47 21 07 81 46
E-mail:
 
Copyright/Disclaimer

Alterations in ATC/DDD

Overview of ATC/DDD alterations decided at the two previous meetings of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the ATC/DDD alterations from the latest meeting (temporary codes) should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the alterations will be considered final and included in the ATC/DDD index. The year of implementation in the ATC/DDD index is given in the list. 

Please note that all ATC and DDD alterations are valid and implemented annually.

Change of DDDs

ATC codeLevel namePrevious DDDNew DDDDeadline for objection to temporary alterations 1) Implementation in ATC/DDD index
A16AX01thioctic acid0.2 g O,P0.6 g O,P01.09.20162017
B02BDBlood coagulation factors 2)deleted 2)Final2017
G03XB01mifepristone0.6 g O0.2 g OFinal2017
J01CR01ampicillin and enzyme inhibitor 2 g 3) P6 g O01.02.20162017
J02AC04posaconazole0.8 g O0.3 g O01.09.20162017
1) Final: indicates that the date for objection has expired
2) DDDs for the various blood coagulation factors in all ATC 5th level codes in B02BD are deleted. No new DDDs will be established in B02BD Blood coagulation factors.
3) Refers to ampicillin

Change of ATC level name

Previous nameNew ATC level nameATC codeDeadline for objection to temporary alterations 1) Implementation in ATC/DDD index
atenolol and other antihypertensivesatenolol and nifedipineC07FB03Final2017
Beta blocking agents and other antihypertensivesBeta blocking agents, other combinationsC07FFinal2017
Beta blocking agents, selective, and other antihypertensivesBeta blocking agents and calcium channel blockersC07FBFinal2017
bisoprolol and other antihypertensivesbisoprolol and amlodipineC07FB07Final2017
nebivolol and other antihypertensivesnevibolol and amlodipineC07FB12Final2017
oxycodone, combinationoxycodone and naloxoneN02AA55Final2017
1) Final: indicates that the date for objection has expired

Change in ATC codes

INN/generic namePrevious ATC codeNew ATC codeDeadline for objection to temporary alterations 1) Implementation in ATC/DDD index
albiglutideA10BX13A10BJ04Final2017
canagliflozinA10BX11A10BK02Final2017
dapagliflozinA10BX09A10BK01Final2017
dulaglutideA10BX14A10BJ05Final2017
empagliflozinA10BX12A10BK03Final2017
exenatideA10BX04A10BJ01Final2017
liraglutideA10BX07A10BJ02Final2017
lixisenatideA10BX10A10BJ03Final2017
mepolizumabL04AC06R03DX09Final2017
methotrexate 2)L01BA01L04AX03Final2017
nonacog alfaB02BD09B02BD04 3)Final2017
tioproninR05CB12G04BX16Final2017
trenonacog alfaB02BD12B02BD04 3)Final2017
1) Final: indicates that the date for objection has expired
2) Splitting of ATC code. Only the classification of pre-filled syringes of methotrexate for use in non-cancer indications is changed. These products will be moved to the existing ATC code for oral administered product of methotrexate. Parenteral preparations used for treatment of cancer will remain in L01BA01.
3) Existing ATC code B02BD04 coagulation factor IX

Last updated: 2016-05-12